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Rationale: To assess in a pragmatic phase III prospective double blind randomised 
placebo-controlled trial whether tranexamic acid is safe and reduces death or dependency 
after spontaneous intracerebral haemorrhage (SICH). The results will determine whether 
tranexamic acid should be used to treat ICH. 
 
Design: Patients will be randomised (1:1) to receive either tranexamic acid or placebo (0.9 
% saline) within 8 hours of acute SICH. Randomisation will be computerised and 
minimised on key prognostics age; sex; time since onset; systolic blood pressure; stroke 
severity (NIHSS); presence of intraventricular haemorrhage and known history of 
antiplatelet treatment. Patients, investigators and outcome assessors will be blind to 
treatment allocation. The primary outcome is death or dependency (modified Rankin 
Scale) and telephone follow-up is at day 90.  
 
Trial status: The start-up phase of the trial commenced on 1st March 2013, the main 
phase commenced 1st April 2014.  The recruitment target was 300 participants in the start-
up phase and 2,000 in the main phase.  As of 30th May 2017, 2191 patients have been 
recruited from 123 centres (UK, Georgia, Italy, Malaysia, Switzerland, Republic of Ireland, 
Turkey, Sweden, Denmark, Hungary, Spain and Poland). The objective was to have 80 
UK centres and 40 international centres. 
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Programme (11/129/109) 
 
Disclaimer:  The views and opinions expressed therein are those of the authors and do 
not necessarily reflect those of the Health and Technology Assessment Programme, 
NIHR, NHS or the Department of Health.  
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